Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of BBR 3464 as First Line Treatment in Patients With Inoperable, Locally Advanced or Metastatic Adenocarcinoma of the Pancreas

NCT00024362 is registered in ClinicalTrials.gov with Theradex as lead sponsor.

NCT NCT00024362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of BBR 3464 as First Line Treatment in Patients With Inoperable, Locally Advanced or Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Theradex
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer